AZIYO BIOLOGICS, INC. PROXICOR FOR CARDIAC TISSUE REPAIR; PATCH, PLEDGET AND INTRACARDIAC-DXZ
|
Back to Search Results |
|
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problem
Valvular Insufficiency/ Regurgitation (4449)
|
Event Date 03/01/2021 |
Event Type
Death
|
Manufacturer Narrative
|
No sample was returned for investigation therefore no manufacturing records could be reviewed as part of aziyo's investigation.While the specific product was not referenced in the article, the authors did make reference to a "large cormatrix patch", which could potentially be the proxicor for cardiac tissue repair, with 7cm x 10cm being the largest size.The instructions for use provided with the proxicor for cardiac tissue repair (art-20700b) lists the indications for use as follows: "proxicor¿ for cardiac tissue repair is indicated for use as an intracardiac patch or pledget for tissue repair (i.E., atrial septal defect (asd), ventricular septal defect (vsd), etc.) and suture-line buttressing." the patch is required to be sutured to viable tissue on all sides.Use of this product to augment valve leaflets is considered to be an off-label use of this product.
|
|
Event Description
|
During post market surveillance, an article entitled "cormatrix anterior leaflet augmentation of the tricuspid valve: midterm results." heart surg forum, 2021 mar 8;24(2): e261-e266 was reviewed and summarized as follows: retrospective analysis of 424 patients undergoing tricuspid valve procedures between 1/2013 and 8/2018: 420 anterior leaflet patch augmentation/repairs & 4 tricuspid valve replacements.Out of the valve repairs cohort, 19 patients had cormatrix (currently aziyo biologics) ecm patches, likely proxicor for cardiac tissue repair - (model# / lot#: unknown) used for anterior leaflet augmentation of tricuspid valve - 5 patients having isolated repair - augmentation only & 14 repairs conducted with concomitant surgeries on another valve.There were two (2) deaths reported at late follow-up.The cause was listed as cardiovascular, and later described by the author as "suboptimal cardiovascular issues." both patients were found to have significant recurrence of regurgitation of the tricuspid valve during post-op testing.The article clearly states that these events were unrelated to aziyo products with statements such as "we had no clear failures related to the patch itself" and "the observed failures were probably unrelated to the [patch] material used." separate mdrs will be filed for other reported adverse events associated with this study.Attempts to obtain additional information about the reported events were unsuccessful.Should any additional information be received, a follow-up report will be filed.
|
|
Search Alerts/Recalls
|
|
|